Unsymmetrical PBD Dimer Conjugates for Targeted DNA Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pyrrolobenzodiazepine (PBD) dimer compounds for targeted conjugates are limited in their synthesis methods and biological properties, particularly in their ability to effectively target proliferative or autoimmune diseases due to symmetrical structures and complex synthesis processes.
Innovation Solution
Development of unsymmetrical PBD dimer compounds with C2 aryl substituents, where each C2 substituent is added separately to a symmetrical PBD dimer core, forming conjugates with a Ligand Unit and a Linker Unit, enabling targeted therapy through specific binding to cellular components or molecules, and allowing for varying drug loading from 1 to 20 PBD units per Ligand Unit.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If symmetrical PBD dimer structures are used, then synthesis is simplified, but biological activity and targeting capability are reduced
Solution Approach 1:
The patent applies asymmetry by introducing different substituents at the C2 and C2' positions of the PBD dimer structure. Specifically, one monomer unit contains a C2 aryl substituent while the other has a different substituent pattern, creating an unsymmetrical dimer that maintains synthetic feasibility while significantly enhancing biological activity and DNA binding specificity.
Solution Approach 2:
The patent implements local quality by placing specific functional groups at particular positions on the PBD dimer. The C2 aryl substituent is strategically positioned on one monomer unit to enhance DNA minor groove binding, while other positions are modified with different groups to optimize both synthesis pathways and biological properties, allowing each part of the molecule to contribute differently to overall function.
2Reliability
If multiple substituents are added to PBD dimer core, then biological properties are enhanced, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis into modular stages: first constructing the PBD dimer core with essential functionality, then sequentially adding the C2 aryl substituent and other functional groups in separate steps. This segmented approach allows each transformation to be optimized independently, managing overall synthesis complexity while achieving enhanced biological properties.
Solution Approach 2:
The patent implements preliminary action by pre-forming the PBD dimer core structure before adding the C2 aryl substituent. This preliminary construction of the core framework with its essential DNA-binding capability allows subsequent substituent additions to be performed under optimized conditions, reducing overall synthesis complexity while enhancing biological properties.
3Manufacturing precision
If C2 aryl substituent is added to PBD dimer, then DNA binding specificity is improved, but manufacturing difficulty increases
Solution Approach 1:
The patent applies parameter changes by modifying the electronic and steric parameters of the PBD dimer through C2 aryl substitution. The aryl group's specific electronic properties (electron-withdrawing or electron-donating characteristics) and steric bulk are tuned to optimize DNA minor groove binding specificity, while the synthesis methodology is adjusted to accommodate this modification without excessive complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The unsymmetrical PBD dimer compounds provide enhanced biological properties and simplified synthesis, enabling effective treatment of proliferative and autoimmune diseases by allowing precise targeting and adjustable drug delivery, as demonstrated by their ability to form sequence-selective DNA lesions and interfere with DNA processing.
Implementation Method 1
The PBD dimers are thought to form sequence-selective DNA lesions such as the palindromic 5'-Pu-GATC-Py-3' interstrand cross-link which is thought to be mainly responsible for their biological activity
Implementation Method 2
Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific sequences of DNA; the preferred sequence is PuGPu
Data Source
Figure 1
AI summary
A Conjugate having formula IV: L - (LU-D)P (IV) or a pharmaceutically acceptable salt or solvate thereof; wherein L is a Ligand Unit selected from the group consisting of an antibody and an antigen-binding fragment of an antibody, LU is a Linker Unit, p is 1 to 20; and D is selected from the group consisting of D1 to D6 having the structures as defined in claim 1 and wherein LU is: wherein the asterisk indicates the point of attachment to D, the wavy line indicates the point of attachment to the Ligand Unit, Y is NH and E is glucuronic acid; and A1 is a Stretcher Unit.